Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Source: SeekingAlpha
2025-07-31 21:35:00 ET
| Advisor Class: FTDZX Class A: FBDIX | Commentary | as of June 30, 2025 |
Key Takeaways
Read the full article on Seeking Alpha
For further details see:
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Akebia Therapeutics Inc.
NASDAQ: AKBA
AKBA Trading
3.19% G/L:
$1.435 Last:
636,270 Volume:
$1.40 Open:
AKBA Latest News
April 13, 2026 08:00:00 am
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090April 07, 2026 08:00:00 am
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation SymposiumApril 01, 2026 04:05:00 pm
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of DirectorsAKBA Stock Data
$399,375,819
257,405,013
0.93%
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
